Filtros de búsqueda

Lista de obras de

A Multicenter, Phase II, Randomized, Noncomparative Clinical Trial of Radiation and Temozolomide with or without Vandetanib in Newly Diagnosed Glioblastoma Patients

artículo científico publicado en 2015

ACTR-76. FINAL RESULTS FROM A PHASE I STUDY OF PLERIXAFOR AND BEVACIZUMAB IN RECURRENT HIGH-GRADE GLIOMA.

artículo científico publicado en 2017

AT-36PANOBINOSTAT IN COMBINATION WITH BEVACIZUMAB FOR RECURRENT GLIOBLASTOMA AND ANAPLASTIC GLIOMA

AT-37PHASE I STUDY OF PLERIXAFOR AND BEVACIZUMAB IN RECURRENT HIGH-GRADE GLIOMA.

artículo científico publicado en 2014

ATIM-32. PERSONALIZED NEOANTIGEN-TARGETING VACCINE GENERATES ROBUST SYSTEMIC AND INTRATUMORAL T CELL RESPONSES IN GLIOBLASTOMA (GBM) PATIENTS

ATNT-14PHASE I STUDY OF PLERIXAFOR AND BEVACIZUMAB IN RECURRENT HIGH-GRADE GLIOMA.

artículo científico publicado en 2015

Buparlisib in Patients With Recurrent Glioblastoma Harboring Phosphatidylinositol 3-Kinase Pathway Activation: An Open-Label, Multicenter, Multi-Arm, Phase II Trial

scientific article published on 04 February 2019

Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial

scientific article published on 19 December 2018

Phase I and biomarker study of plerixafor and bevacizumab in recurrent high-grade glioma.

artículo científico publicado en 2018

Phase II study of monthly pasireotide LAR (SOM230C) for recurrent or progressive meningioma

artículo científico publicado en 2014

Phase II study of panobinostat in combination with bevacizumab for recurrent glioblastoma and anaplastic glioma

artículo científico publicado en 2015

Phase II trial of triple tyrosine kinase receptor inhibitor nintedanib in recurrent high-grade gliomas.

artículo científico publicado en 2014

Dominio Público Uruguay está sostenido por:

Acerca de Dominio Público Uruguay

Ayuda